WO2018031894A1 - Tissue specific markers for preoperative and intraoperative localization and visualization of tissue - Google Patents

Tissue specific markers for preoperative and intraoperative localization and visualization of tissue Download PDF

Info

Publication number
WO2018031894A1
WO2018031894A1 PCT/US2017/046514 US2017046514W WO2018031894A1 WO 2018031894 A1 WO2018031894 A1 WO 2018031894A1 US 2017046514 W US2017046514 W US 2017046514W WO 2018031894 A1 WO2018031894 A1 WO 2018031894A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
seq
aptamer
specific marker
parathyroid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/046514
Other languages
English (en)
French (fr)
Inventor
Dennise DALMA-WEISZHAUSZ
Alex Vayser
James BREDENKAMP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Invuity Inc
Original Assignee
Invuity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invuity Inc filed Critical Invuity Inc
Priority to CA3033188A priority Critical patent/CA3033188A1/en
Priority to CN201780062879.4A priority patent/CN109804071A/zh
Priority to AU2017308059A priority patent/AU2017308059A1/en
Priority to EP17840344.0A priority patent/EP3497244A4/en
Priority to JP2019507152A priority patent/JP2019531706A/ja
Publication of WO2018031894A1 publication Critical patent/WO2018031894A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • A61B2090/3937—Visible markers
    • A61B2090/395—Visible markers with marking agent for marking skin or other tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4887—Locating particular structures in or on the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Definitions

  • a thyroidectomy is an operation that removes at least part of the thyroid gland, a butterfly-shaped gland located at the base of the neck.
  • hypocalcemia or hypoparathyroidism is an operation that removes at least part of the thyroid gland, a butterfly-shaped gland located at the base of the neck.
  • Hypocalcemia or hypoparathyroidism is an operation that removes at least part of the thyroid gland, a butterfly-shaped gland located at the base of the neck.
  • hypocalcemia or hypoparathyroidism is an operation that removes at least part of the thyroid gland, a butterfly-shaped gland located at the base of the neck.
  • Calcium regulation in the body is managed by a group of small bean-sized glands called the parathyroids.
  • Hypocalcemia or hypoparathyroidism after a thyroidectomy occurs because of the accidental removal of the parathyroid glands during the thyroidectomy.
  • parathyroids are small glands whose location varies from patient to patient, making it difficult to dissect only the portion of the thyroid that is affected without accidentally removing the small parathyroid glands that are in close proximity. Enabling the surgeon to easily identify the location of the parathyroids relative to the altered or affected thyroid tissue would allow them to do a more precise thyroid-only dissection sparing the small parathyroid glands.
  • parathyroidectomy the surgical removal of at least one of the parathyroid glands, which is the most common and effective treatment for hyperparathyroidism, a condition that is caused by a benign tumor (parathyroid adenoma) or an enlargement
  • PTH Parathyroid Hormone
  • the surgeon removes the affected gland(s), the PTH level will usually return to normal.
  • the surgeon must decide where to make an incision and once the incision is made, he must also differentiate the parathyroid tissue from neighboring tissues. This is challenging because the parathyroid glands are small and difficult to locate among other structures in the neck such as thyroid, lymph nodes, etc. The exact location of these small glands may also vary from patient to patient.
  • the patients may not want significant scarring on their neck, which is an often exposed part of the body; as such, surgeons may want to make the smallest and fewest possible incisions. Precisely locating these small glands before selecting surgical incision sites may enable surgeons to reduce the number and size of incisions and by extension, the discomfort of post-surgery recovery and scarring.
  • Current strategies for the preoperative identification of the parathyroid (e.g., adenoma) gland location include Sestamibi (99-Technetium) scans, ultrasound and in some cases computed tomography (CT) scans, but these are costly and not perfectly reliable. Affordable and precise tools and methods that allow surgeons to preoperatively identify the location, size and health of the glands and
  • 5R00CA153916-05 Quyen Nguyen. Testing fluorescently labelled probes for nerve imaging during surgery. 5R01EB014929-03; Brian W. Pogue and Keith Paulsen. Molecular fluorescence- guided surgery platform. 5R01CA167413-02; Marcin Ptaszek. Novel activatable fluorophores for multicolor fluorescence-guided cancer surgery. 1U01CA181628-01; Brian Straight. Intraoperative assessment of non-melanoma skin cancer margins using NIRF probes.
  • Patents/Patent Publications US8,685,372, US2014/0140594, US2014/0276008,
  • the claimed invention in some aspects, relates to surgical tools and methods, and in some more particular aspects relates to tissue specific markers that facilitate the identification of target tissue from adjacent tissue, or a system which includes the marker and methods of use of the marker or markers.
  • a tissue specific marker comprises an aptamer or an affimer configured to bind to a pre-selected target tissue, and one or more indicator elements coupled to the aptamer or the affimer.
  • the one or more indicator elements may produce a signal including spectral, paramagnetic, acoustic, etc. thereby allowing identification of the target tissue.
  • a tissue specific marker comprises an aptamer or an affimer configured to selectively bind to a non-malignant target tissue and/or a normal tissue; and at least a first indicator element coupled to the aptamer or the affimer, wherein the at least a first indicator element produces a signal, thereby allowing identification of the non-malignant target tissue.
  • the tissue specific marker comprises the aptamer configured to selectively bind to the non-malignant target tissue (and/or the normal tissue), wherein the aptamer comprises DNA, RNA, a peptide, or any combination thereof.
  • the aptamer comprises a nucleic acid, peptides, DNA, RNA, or modified nucleotides or nucleosides. In some embodiments, the aptamer or the affimer is PEGylated or otherwise altered for increased stability. In some embodiments, the aptamer comprises RNA or DNA, or both RNA and DNA. In some embodiments, the aptamer is an RNA aptamer. In some embodiments, the aptamer is a DNA aptamer. In some embodiments, the aptamer comprises an inverted T at a 3' end of the aptamer, e.g., an inverted T at a 3' end of a nucleic acid aptamer.
  • the aptamer has a length of up to 100 nucleotides.
  • the non-malignant target tissue comprises a parathyroid gland or a parathyroid adenoma. In some embodiments, the non-malignant target tissue comprises a parathyroid. In some embodiments, the non-malignant target tissue is a human tissue. In some embodiments, the non-malignant target tissue is a non-human tissue. In some embodiments, the non-malignant target tissue is a gland tissue. In some embodiments, the gland tissue is an exocrine gland tissue or an endocrine gland tissue.
  • the target tissue is a healthy tissue, normal tissue and/or non- malignant tissue.
  • the non-malignant tissue is a non-adipose, healthy tissue.
  • the non-malignant tissue is a healthy tissue that is not adipose tissue.
  • the non-malignant tissue is not a healthy tissue.
  • the signal produced can be within the magnetic, acoustic, visible, near-infrared, and infrared spectra.
  • the aptamer binds to the non-malignant target tissue with an affinity within a range of 1 pM to 1 mM.
  • the aptamer selectively binds to the target tissue with an affinity at least 10-fold higher than an affinity of the aptamer binding to a non-target tissue. In some embodiments, the aptamer selectively binds to the non- malignant target tissue with an affinity at least 2-fold higher than an affinity of the aptamer binding to a non-target tissue. In some embodiments, the non-target tissue comprises a thyroid. In some embodiments, the non-malignant target tissue is a non-human tissue. In some embodiments, the target tissue comprises a parathyroid gland or a parathyroid adenoma. In some embodiments, the non-malignant target tissue comprises a parathyroid. In some embodiments, the non-malignant target tissue comprises a nerve, a blood vessel, a ureter, a bile duct, endometrial tissue, hepatic duct, lymph nodes, bacteria or fungus.
  • the aptamer or the affimer is configured to selectively bind to a first gland over a second gland. In some embodiments, the aptamer or the affimer is configured to preferentially bind the non-malignant target tissue over a tissue situated adjacent to the non- malignant target tissue.
  • the aptamer or the affimer is configured to preferentially bind the gland tissue over at least one tissue selected from the group consisting of adipose, thymus, lymph node and pharynx tissue. In some embodiments, the aptamer or the affimer is configured to selectively bind to a healthy parathyroid tissue or a parathyroid adenoma tissue. In some embodiments, the aptamer or the affimer is configured to selectively bind to both the healthy parathyroid tissue and the parathyroid adenoma tissue.
  • the aptamer or the affimer preferentially binds to the healthy parathyroid tissue or the parathyroid adenoma tissue over a thyroid tissue. In some embodiments, the aptamer or the affimer preferentially binds to the healthy parathyroid tissue and the parathyroid adenoma tissue over the thyroid tissue. In some embodiments, the aptamer or the affimer preferentially binds to the healthy parathyroid tissue or the parathyroid adenoma tissue over at least one tissue selected from the group consisting of adipose, thymus, lymph node and pharynx tissue.
  • the non-malignant target tissue comprises a nerve, a blood vessel, a ureter, a bile duct, endometrial tissue, hepatic duct, lymph nodes, bacteria or fungus.
  • the non-malignant target tissue comprises female reproductive tissues such as endometrium or uterus.
  • the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NOs: 1-200. In some embodiments, the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NOs: 1- 10 and SEQ ID NOs: 100-110.
  • the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, or SEQ ID NO: 105.
  • the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 103, or SEQ ID NO: 104.
  • the aptamer comprises a sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 103, or SEQ ID NO: 104.
  • the aptamer comprises a sequence that includes the motif GAT ACTG.
  • the target tissue may comprise, for example, a parathyroid gland or a parathyroid adenoma.
  • the target tissue may also comprise an organ, a nerve, a blood vessel, a ureter, endometrium, the thyroid, a bile duct, a hepatic duct, lymph nodes, bacteria, fungus or malignant tissue.
  • the one or more indicator elements or the at least a first indicator produces the signal when exposed to or excited by energy, or may be detectable by any other known method.
  • the signal produced is within a magnetic, acoustic, visible, near-infrared, or infrared spectrum.
  • the at least a first indicator element comprises a fluorophore.
  • the fluorophore is near-infrared dye, a cyanine dye or indocyanine green.
  • the one or more indicator elements or the at least a first indicator element comprise a fluorophore, a quantum dot, a dye, a nanodiamond, an enzyme, a protein, a nanocrystal, gold or iron oxide particles, an optoacoustic converter element that converts light or near infrared signal to an acoustic output, a nanoparticle, nanorod, bead, or combination thereof.
  • the at least a first indicator element is covalently coupled to the aptamer, the affimer, or a second indicator element.
  • the at least a first indicator element comprises a first indicator element that is a fluorophore and a second indicator element that is a nanodiamond.
  • two or more tissue specific markers may be used, wherein the second tissue specific marker comprises a second aptamer or affimer configured to bind to a second pre-selected target tissue different than the first pre-selected target tissue.
  • the first pre-selected target tissue is parathyroid tissue and the second pre-selected target tissue is thyroid tissue.
  • the one or more indicator elements may be coupled to an aptamer, an affimer, or one or more other indicator elements. In some cases, one of the indicator elements will be detectable at a deeper distance. This may allow the surgeon to identify a target tissue
  • a system for differentiating target tissue from adjacent tissue comprises any of the aspects of the marker described herein, and a probe or device for exciting the marker with energy and/or a probe or detector for detecting the spectral signal from the one or more indicator elements.
  • the excitation device (or probe) and the detector (or probe) may be the same device (or probe), or they may be different devices (probes).
  • a system for differentiating a target tissue from an adjacent tissue comprises the tissue specific marker as described herein and a device for exciting the tissue specific marker with energy and/or a detector for detecting the signal from the one or more indicator elements.
  • the device for exciting the tissue specific marker with energy is an illumination source.
  • the detector comprises a camera.
  • a system for differentiating a target tissue from an adjacent tissue may comprise the tissue specific marker as described herein, a second tissue specific marker, comprising a second aptamer or a second affimer configured to bind to a second target tissue and a second indicator element coupled with the second aptamer or the second affimer, wherein the second indicator element produces a signal thereby allowing identification of the second target tissue and a first device for exciting the tissue specific marker with energy or a detector for detecting the signal from any of the first or second indicator elements, or from both the first and second indicator elements.
  • the system comprises an illumination source.
  • the system comprises a camera.
  • a non-malignant target tissue is a parathyroid tissue and the first indicator element is a first fluorophore and wherein the second target tissue is nerve, lymph node, or thyroid tissue and the second indicator element is a second fluorophore different from the first fluorophore.
  • a method for differentiating tissue comprises delivering an aptamer or an affimer coupled to the one or more indicator elements into a patient's or a subject's body, allowing the aptamer or the affimer to bind to a target tissue, a normal or a non-malignant target tissue, detecting a signal produced by the one or more indicator elements or detecting the one or more indicator elements, and identifying the target tissue(s) from adjacent tissue based on the detected signal or distinguishing the normal or non-malignant target tissue from an adjacent tissue based on the signal detected from the one or more indicator elements.
  • the method comprises exposing or exciting the one or more indicator elements that are coupled to the aptamer or the affimer with energy.
  • the method comprises delivering the aptamer or the affimer or the tissue specific marker comprises transdermally delivering, spraying, flooding, orally delivering, or intravenously delivering the aptamer or the affimer to the non-malignant target tissue.
  • the method further comprises performing a medical procedure on the target tissue without damaging adjacent tissue.
  • the method may comprise removing at least a portion of the thyroid gland without damaging adjacent normal parathyroid tissues.
  • the target tissue may comprise one or more abnormal (e.g., adenoma, hyperplasia or malignant tumor) parathyroid glands during a parathyroidectomy.
  • the method comprises delivering the aptamer or the affimer comprises a washing step.
  • the method further comprises performing a medical procedure on the adjacent tissue without damaging the non-malignant target tissue, or without significantly damaging the non-malignant target tissue.
  • the method comprises performing a medical procedure on the non-malignant target tissue without damaging the adjacent tissue.
  • the non-malignant target tissue is a parathyroid adenoma and the method further comprises removing at least a portion of the parathyroid adenoma without damaging an adjacent thyroid tissue.
  • the non-malignant target tissue is a parathyroid tissue, and the method further comprises removing at least a portion of the adjacent thyroid tissue without damaging or removing the parathyroid tissue.
  • the aptamer or the affimer selectively binds to a healthy parathyroid tissue or a parathyroid adenoma tissue. In some embodiments, the aptamer or the affimer selectively binds to both the healthy parathyroid tissue and the parathyroid adenoma tissue. In some embodiments, the aptamer or the affimer selectively binds to both the healthy parathyroid tissue and the parathyroid adenoma tissue over the adjacent thyroid tissue.
  • the method comprises detecting a first set of the one or more indicator elements and a second set of the one or more indicator elements, wherein the first set is detected at a greater distance from the tissue specific marker than the second set.
  • the first set is detected outside the subject's body and the second set is detected after a surgical incision is made.
  • identifying the non-malignant target tissue comprises visualizing the signal from the one or more indicator elements.
  • detecting the signal from the one or more indicator elements comprises detecting a spectral signal with a detector.
  • detecting the signal from the one or more indicator elements comprises detecting a spectral signal with a camera.
  • the method further comprising forming a diagnosis based on the detected spectral signal.
  • detecting the signal from the one or more indicator elements comprises detecting the signal preoperatively.
  • detecting the signal from the one or more indicator elements comprises detecting the signal intraoperatively.
  • the method may comprise the detection of at least two different indicator elements.
  • at least two different indicator elements are the same type of indicator element such as a fluorophore and are distinguishable by color or emission wavelength.
  • the two different indicator elements are different types of indicator elements.
  • a first indicator element may be an Indocyanine Green (ICG) fluorophore or a pH sensitive indicator and the second indicator element may be a nanodiamond.
  • ICG Indocyanine Green
  • a first indicator element produces a signal that is detectable when the probe is placed at a first distance from the labeled tissue and a second indicator element produces a signal that is detectable at a second distance that is greater than the first distance.
  • a first indicator element may be detected after a surgical incision is made and a second indicator element may be detected outside the body (e.g., through the skin).
  • the first and second indicator elements produce different types of signals.
  • the method comprises detecting the signal from the one or more indicator elements using a probe or other device.
  • identifying the target tissue may comprise visualizing a signal emitted from the one or more indicator elements.
  • Detecting the signal may comprise detecting the one or more indicator elements with a camera, for example a complementary metal-oxide-semiconductor (CMOS) camera or a charge coupled display (CCD) camera. Detecting the signal from the one or more indicator elements may be used diagnostically, or non-diagnostically, preoperatively, intraoperatively or in any combination of these applications.
  • CMOS complementary metal-oxide-semiconductor
  • CCD charge coupled display
  • a tissue specific marker comprising: an aptamer or an affimer configured to bind to a pre-selected target tissue; and at least a first indicator element coupled to the aptamer or the affimer, wherein the at least a first indicator element produces a signal allowing identification of the target tissue.
  • the aptamer comprises DNA, RNA, or a peptide, or any combination thereof.
  • the aptamer comprises modified nucleotides or nucleosides.
  • the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%>, at least 85%>, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NOs: 1- 200. In some embodiments, the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NOs: 1-10 and SEQ ID NOs: 100-110.
  • the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, or SEQ ID NO: 105.
  • the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 103, or SEQ ID NO: 104.
  • the aptamer comprises a sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 103, or SEQ ID NO: 104.
  • the aptamer comprises a sequence that includes the motif GATACTG.
  • the aptamer has a length of up to 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, or 200
  • the aptamer binds to the target tissue with an affinity within a range of 1 pM to 1 mM, such as within a range of 1 nM to 100 ⁇ .
  • the target tissue is a healthy tissue, normal tissue and/or non- malignant tissue.
  • the non-malignant tissue is a non-adipose, healthy tissue.
  • the non-malignant tissue is a healthy tissue that is not adipose tissue.
  • the non-malignant tissue is not a healthy tissue.
  • the signal produced can be within the magnetic, acoustic, visible, near-infrared, and infrared spectra.
  • the aptamer selectively binds to the target tissue with an affinity at least 10-fold higher than an affinity of the aptamer binding to a non-target tissue.
  • the aptamer selectively binds to the non-malignant target tissue with an affinity at least 2-fold higher than an affinity of the aptamer binding to a non-target tissue.
  • the non-malignant target tissue comprises a parathyroid gland or a parathyroid adenoma.
  • the non-target tissue comprises a thyroid.
  • the non-malignant target tissue is a human tissue.
  • the non- malignant target tissue is a non-human tissue.
  • the target tissue comprises a parathyroid gland or a parathyroid adenoma.
  • the non-malignant target tissue comprises a nerve, a blood vessel, a ureter, a bile duct, endometrial tissue, hepatic duct, lymph nodes, bacteria or fungus.
  • the at least a first indicator element comprises a fluorophore.
  • the fluorophore is a near-infrared dye.
  • the fluorophore is a cyanine dye.
  • the fluorophore is indocyanine green.
  • the at least a first indicator element comprises a quantum dot.
  • the at least a first indicator element comprises an enzyme or protein.
  • the at least a first indicator element comprises a pH sensitive indicator.
  • the at least a first indicator element comprises a nanodiamond.
  • the at least a first indicator element comprises an optoacoustic converter element.
  • the at least a first indicator element comprises a nanoparticle or nanorod. In some embodiments, the at least a first indicator element comprises a bead. In some embodiments, the at least a first indicator element is covalently coupled to the aptamer, the affimer, a second indicator element or the one or more indicator elements.
  • a system for differentiating target tissue from adjacent tissue further comprises a marker described herein and a probe for exciting the marker with energy or a probe for detecting the signal from the one or more indicator elements.
  • the system further comprises an illumination source.
  • the system further comprises a camera.
  • a system for differentiating target tissue from adjacent tissue further comprises a marker described herein, a second tissue specific marker, comprising a second aptamer or a second affimer configured to bind to a second preselected target tissue and one or more second indicator elements coupled with the second aptamer or the second affimer, wherein the second indicator element produces a spectral signal when exposed to or excited by energy thereby allowing identification of the second target tissue, a first probe for exciting the marker with energy or a probe for detecting the spectral signal from the one or more indicator elements and a second probe for exciting the marker with energy or a probe for detecting the spectral signal from the one or more second indicator elements.
  • the system further comprises an illumination source.
  • the system further comprises a camera.
  • a method for differentiating tissue comprises delivering an aptamer or an affimer coupled to one or more indicator elements into a patient's body, allowing the aptamer or the affimer to bind with a target tissue in the patient's body, exposing or exciting the one or more indicator elements with energy, detecting a signal produced by the one or more indicator elements or detecting the one or more indicator elements and distinguishing the target tissue from adjacent tissue based on the signal detected from the one or more indicator elements.
  • a method comprises delivering a second aptamer or a second affimer coupled to one or more indicator elements into a subject's body, allowing the second aptamer or the second affimer to bind with a second target tissue, wherein the second target tissue is different than a target tissue, exposing or exciting the one or more indicator elements that are coupled to the second aptamer or the second affimer with energy, detecting a spectral signal produced by the one or more indicator elements that are coupled to the second aptamer or the second affimer or detecting the one or more indicator elements that are coupled to the second aptamer or the second affimer and identifying the second target tissue from the target tissue based on the signal detected from the one or more indicator elements that are coupled to the second aptamer or the second affimer.
  • delivering an aptamer or an affimer comprises transdermally delivering, spraying, flooding, orally delivering, or intravenously delivering the aptamer or the affimer to the target tissue.
  • delivering the aptamer or affimer comprises a washing step.
  • the method further comprises performing a medical procedure on the non- malignant target tissue without damaging adjacent tissue.
  • the target tissue is a thyroid gland, and the method further comprises removing at least a portion of the thyroid gland without damaging adjacent parathyroid tissue.
  • the target tissue is a parathyroid gland, and the method further comprises removing one or more parathyroid glands without damaging or removing adjacent thyroid.
  • the method further comprises detecting a first set of the one or more indicator elements and a second set of the one or more indicator elements, wherein the first set is detected at a greater distance from the tissue specific marker than the second set. In some cases, the first set is detected outside the body and the second set is detected after a surgical incision is made.
  • identifying the target tissue comprises visualizing the signal from the one or more indicator elements.
  • detecting the signal from the one or more indicator elements comprises detecting the signal with a probe.
  • detecting the signal from the one or more indicator elements comprises detecting the spectral signal with a camera.
  • the method further comprises forming a diagnosis based on the detected signal.
  • detecting the signal from the one or more indicator elements comprises detecting the signal preoperatively.
  • detecting the signal from the one or more indicator elements comprises detecting the signal intraoperatively.
  • the method further comprises delivering a second aptamer or a second affimer coupled to one or more indicator elements into a patient's or the subject's body; allowing the second aptamer or the second affimer to bind with a second target tissue, wherein the second target tissue is different than the normal or non-malignant target tissue; exposing or exciting the one or more indicator elements that are coupled to the second aptamer or the second affimer; detecting a signal produced by the one or more indicator elements that are coupled to the second aptamer or the second affimer or detecting the one or more indicator elements that are coupled to the second aptamer or the second affimer; and identifying the second target tissue from the normal or non-malignant target tissue based on the signal detected from the one or more indicator elements that are coupled to the second aptamer or the second affimer.
  • an aptamer that selectively binds to a parathyroid gland or a parathyroid adenoma.
  • the aptamer selectively binds to the parathyroid gland or the parathyroid adenoma over a thyroid gland.
  • the aptamer selectively binds to the parathyroid gland or the parathyroid adenoma with an affinity at least 10- fold higher than an affinity of the aptamer for binding to a thyroid gland.
  • the aptamer selectively binds to the parathyroid gland or the parathyroid adenoma with an affinity at least 5-fold, 10-fold, at least 20-fold, at least 50-fold, or at least 100-fold higher than an affinity of the aptamer binding to a thyroid gland.
  • the aptamer comprises DNA.
  • the aptamer comprises RNA.
  • the aptamer, the aptamer selectively binds to a normal, healthy, and/or non-malignant parathyroid gland.
  • the aptamer is configured to selectively bind to both healthy parathyroid tissue and parathyroid adenoma tissue.
  • the aptamer preferentially binds to healthy parathyroid tissue or parathyroid adenoma tissue over a thyroid tissue. In some embodiments, the aptamer preferentially binds to healthy parathyroid tissue and parathyroid adenoma tissue over a thyroid tissue. In some embodiments, the aptamer
  • the aptamer preferentially binds to healthy parathyroid tissue or parathyroid adenoma tissue over at least one tissue selected from the group consisting of adipose, thymus, lymph node and pharynx tissue.
  • the aptamer selectively binds to human tissue.
  • the aptamer is configured to selectively bind to parathyroid tissue over a different type of gland tissue.
  • the aptamer is configured to preferentially bind normal, healthy, or non-malignant target tissue over a tissue situated adjacent to the normal, healthy, or non- malignant target tissue.
  • the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NOs: 1-200.
  • the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%>, at least 85%>, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NOs: 1- 10 and SEQ ID NOs: 100-110.
  • the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, or SEQ ID NO: 105.
  • the aptamer comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 103, or SEQ ID NO: 104. In some cases, the aptamer comprises a sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 103, or SEQ ID NO: 104. In some cases, the aptamer comprises a sequence of GATACTG.
  • a polynucleotide comprising a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%), or 100%) sequence identity to any one of SEQ ID NOs: 1-200.
  • a polynucleotide comprising a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%), or 100%) sequence identity to any one of SEQ ID NOs: 1-200.
  • polynucleotide comprises a sequence with at least 70% sequence identity to any one of SEQ ID NOs: 1-200, wherein the sequence comprises a non-natural sequence of at least ten contiguous nucleotides or the sequence comprises at least one modified nucleotide.
  • the polynucleotide comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to any one of SEQ ID NOs: 1-10 and SEQ ID NOs: 100-110.
  • the polynucleotide comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, or SEQ ID NO: 105.
  • the polynucleotide comprises a sequence with at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 103, or SEQ ID NO: 104. In some cases, the polynucleotide comprises a sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO: 103, or SEQ ID NO: 104. In some cases, the polynucleotide comprises a sequence of GATACTG.
  • Figure 1 illustrates the anterior view of the thyroid and parathyroid tissues and related anatomy.
  • Figure 2 illustrates the liver, gallbladder and adjacent vasculature.
  • Figure 3 illustrates the renal system and adjacent nerve tissue.
  • Figure 4 illustrates the peripheral nerve system.
  • Figure 5 illustrates the use of the markers to identify lymph nodes.
  • Figure 6 illustrates the sinuses and the application of markers targeted to bacteria.
  • Figure 7 illustrates the use of the probe in identifying cancer or any malignant tissue.
  • Figures 8A-8C illustrate exemplary configurations of a tissue specific marker.
  • Figure 9 illustrates a flowchart for intraoperative use of the tissue specific marker.
  • Figures 10A-10F illustrate use of a tissue specific marker in parathyroidectomy and thyroidectomy.
  • Figure 11 illustrates a flowchart for possible combination of preoperative and
  • tissue specific marker intraoperative use of the tissue specific marker.
  • Figures 12A-12B illustrate the use of a probe for diagnostic or preoperative detection of the tissue specific marker.
  • Figure 13 illustrates an exemplary strategy for selecting a parathyroid-specific marker.
  • Figure 14 illustrates the copy number for 10 sequences, plotted against the selection round.
  • Figure 15 illustrates a sequence alignment of aptamer SEQ ID NO: 103 and SEQ ID NO: 104.
  • Figure 16 shows the protocol for aptamer binding on tissue slides.
  • Figure 17A-17G illustrates binding of aptamer SEQ ID NO:3 to normal parathyroid tissue.
  • Figures 18A-18G Illustrate binding of aptamer SEQ ID NO:4 to normal parathyroid tissue.
  • Figures 19A-19B illustrate binding results of aptamer SEQ ID NO:3 to normal thyroid tissue and binding of SEQ ID NO:4 to normal thyroid tissue.
  • Figures 20A and 20B illustrate binding results of aptamer SEQ ID NO: 3 and aptamer SEQ ID NO:4 on parathyroid adenoma, respectively.
  • Figures 21A and 21B illustrate binding results of aptamer SEQ ID NO:3 and SEQ ID NO:4 on additional normal parathyroid tissues, respectively.
  • Figures 22A and 22B illustrate binding results of aptamer SEQ ID NO: 3 and aptamer SEQ ID NO:4 to adipose tissue, respectively.
  • Figures 23A and 23B illustrate binding results of aptamer SEQ ID NO: 3 and aptamer SEQ ID NO:4 to lymph node, respectively.
  • Figures 24A and 24B illustrate binding results of aptamer SEQ ID NO: 3 and aptamer SEQ ID NO:4 to oropharynx tissue, respectively.
  • Figures 25A and 25B illustrate binding results of aptamer SEQ ID NO: 3 and aptamer SEQ ID NO:4 to thymus tissue, respectively.
  • Figure 26A and 26B show the map of the different tissues on a tissue microarray slide.
  • 26A shows a schematic of the localization of the tissues;
  • Figure 26B shows a picture of the actual microarray slide.
  • Figures 27A-27AH illustrate binding results of aptamer SEQ ID NO: 3 on additional healthy human tissues (tissue microarray).
  • Figures 28A-28AG illustrate binding results of aptamer SEQ ID NO:4 on additional healthy human tissues (tissue microarray).
  • tissue specific marker compositions that can be used to identify or mark a particular tissue (e.g., healthy parathyroid tissue) during preoperative and
  • the tissue specific marker is used to mark a specific healthy tissue (e.g., parathyroid tissue) in order to distinguish it from a different tissue type (e.g., thyroid tissue, adipose tissue,) or diseased tissue (e.g., adenoma, hyperplasia or thyroid malignant tumor).
  • a specific healthy tissue e.g., parathyroid tissue
  • a different tissue type e.g., thyroid tissue, adipose tissue,
  • diseased tissue e.g., adenoma, hyperplasia or thyroid malignant tumor.
  • the tissue specific marker compositions are used to mark healthy tissue to be avoided or preserved during surgery.
  • the tissue specific marker compositions are used to mark diseased tissue or other target tissue for surgical removal.
  • multiple tissue specific markers may be used.
  • a first tissue specific marker may be used to mark one tissue type (e.g., healthy tissue) while a second tissue specific marker is used to mark a different tissue type (e.g., diseased tissue, tissue from a different organ).
  • a single tissue specific marker may contain a first targeting element linked to a second targeting element, wherein the first and second targeting elements are designed to mark different types of tissue, so that two tissues in close proximity to the target tissue can be highlighted.
  • the exemplary embodiments are primarily directed at tissue differentiation of thyroid, parathyroid, or adjacent tissue, this is not intended to be limiting, and one of skill in the art will appreciate that the markers, methods, and systems described here may be used to differentiate any target tissue.
  • the identified or targeted tissue may be organ tissue, particularly tissue from a solid organ or gland.
  • the target tissue is parathyroid tissue, nerve tissue or reproductive tissue (e.g., tissue derived from cervix, ovary, endometrium or other female reproductive organ).
  • the target tissue is a healthy parathyroid tissue , a non-malignant parathyroid tissue, a normal parathyroid tissue or a diseased parathyroid tissue such as parathyroid adenoma tissue, parathyroid hyperplasia tissue or tissue of a parathyroid malignant tumor tissue.
  • FIG. 1 is a schematic diagram of the location of the thyroid 120 and parathyroid glands 125 from the anterior view with the head 110 and body 145 of the patient depicted for perspective. Healthy parathyroid glands 125 and diseased adenoma tissue 130 are shown relative to the larynx 115, the thyroid 120, the thyroid cartilage 135, and the trachea 140. The parathyroid glands 125 are small relative to the adjacent thyroid tissue 120, and there is significant patient-to-patient variability in the exact location of the parathyroid glands. These characteristics pose preoperative and intraoperative challenges to surgeons conducting parathyroidectomy and thyroidectomy procedures.
  • Tissue specific marker compositions may be used to mark or identify parathyroid tissue during a thyroidectomy, thereby preventing unnecessary excision or damage to parathyroid tissue during the procedure.
  • the tissue specific marker composition may be capable of identifying both diseased and healthy tissue.
  • a tissue specific marker may specifically bind both healthy and diseased parathyroid tissue (e.g., parathyroid adenoma tissue).
  • tissue specific marker may also be useful during a parathyroidectomy in order to mark both the diseased parathyroid tissue (e.g., parathyroid adenoma tissue) and the healthy parathyroid tissue in order to avoid unnecessary removal or damage to thyroid tissue.
  • the diseased parathyroid tissue may be located preoperatively using a standard procedure such as a computed tomography (CT) scan, which may identify the quadrant in which the parathyroid adenoma or other diseased tissue is located.
  • CT computed tomography
  • the surgeon may then make an incision in the general region in which the adenoma or diseased tissue is expected to be located and then use the tissue specific marker to more specifically identify the precise location of the adenoma tissue.
  • a blood test to detect parathyroid function such as a parathyroid hormone (PTH) test may be performed in order to provide further assurance that the adenoma tissue was removed.
  • PTH parathyroid hormone
  • a patient may receive systemic administration of a tissue specific marker with a first indicator element and a second indicator element.
  • the parathyroid tissue (diseased or healthy) may then be identified and located preoperatively using a device or probe that detects signal from the first indicator element above the skin, therefore avoiding the use of MRI or Sestamibi scan.
  • This approach may give the surgeon a more accurate indication of the location of the parathyroid tissue so that the initial incision can be even more targeted or precise.
  • the parathyroid may be visualized using the second indicator element.
  • the tissue specific marker contains a single indicator element that is detected preoperatively and/or during surgery.
  • the parathyroid-specific marker may be used with a thyroid-specific marker in order to further assist with differentiation between parathyroid and thyroid tissue.
  • a thyroid-specific marker may be used alone or in conjunction with a parathyroid-specific marker.
  • the tissue specific marker compositions provided herein may be used to mark or identify parathyroid tissue (healthy and/or diseased), thereby preventing unnecessary excision or damage to parathyroid glands during a thyroidectomy procedure. In such cases, the surgeon may focus on removing unmarked thyroid tissue, rather than the marked parathyroid tissue.
  • the parathyroid-specific marker may be used with a thyroid-specific marker in order to further aid in the differentiation between parathyroid and thyroid tissue during a thyroidectomy.
  • a thyroid-specific marker may be used singly or in conjunction with a parathyroid-specific marker.
  • compositions and methods provided herein may be used in any other surgical procedures involving target tissue that is difficult to distinguish from adjacent or neighboring tissue.
  • Figures 2-7 illustrate examples of other regions of the body or tissues that may be operated on and which may benefit from the tissue specific markers and methods of use disclosed herein.
  • FIG. 2 is a schematic diagram showing the hepatic duct 245 and the bile duct 235 relative to adjacent vasculature 210, the aorta 215, inferior vena cava 220, minor hepatic arteries 225, the gall bladder 230, the portal vein 240, the hepatic artery 250, and the liver 255.
  • a tissue specific marker may be applied in diagnostic, preoperative or intraoperative surgical procedures related to the hepatic duct and the bile duct as well as vasculature including vasculature in or around the depicted region of a patient's body. The tissue specific marker may be valuable for perfusion studies and may assist surgeons to avoid nicking blood vessels during surgery.
  • FIG. 3 is a schematic diagram showing the location of the ureters 320 relative to the spine 310, exemplary adjacent nerve tissue 315 originating from the spine 310, the bladder 325, pelvis 330, kidneys 335 and the spinal cord 340.
  • the tissue specific marker may be applied in diagnostic, preoperative or intraoperative surgical procedures related to the ureters as well as nerve tissue including nerve tissue in or around the depicted region of a patient's body.
  • the tissue specific marker can also be selected to bind to a non-solid target, for example one that goes through an anatomic lumen such as urine, and this may be another way for ureter identification and preservation.
  • FIG 4 is a schematic diagram showing the peripheral nerves 315, connected to the spine 310, in more detail, and tissue specific markers may be used to visualize either the CNS tissue or the peripheral nerves or both.
  • tissue specific markers may be used to identify the nerves. Use of these tissue specific markers may allow a surgeon to see the location of one or more nerves during the operation thereby allowing better guidance and therefore providing a higher safety factor for a successful outcome, for example by preventing accidental nicking of a nerve.
  • FIG. 5 is a schematic diagram showing another potential application of these tissue specific markers for distinguishing sentinel lymph nodes 350 or auxiliary lymph nodes 345 from adjacent tissue; the patient's breast 355 is shown for perspective.
  • the markers may be used for identifying the sentinel lymph node during surgical removal of cancerous breast tissue. Visualizing the sentinel lymph node reduces injury to the rest of the anatomy.
  • FIG. 6 is a schematic diagram showing the frontal sinus 365 and the maxillary sinus 380 relative to the superior 360, middle 370 and inferior 375 turbinate bones.
  • bacteria may accumulate in the sinus 385, and cause a sinus infection.
  • Tissue specific markers may also be comprised of aptamers that can bind to a bacteria or fungus and detect an infection site. These infectious-agent specific markers may be used for chronic sinusitis or wound care, and they may enable doctors or surgeons to image an infected region and facilitate patient specific treatment.
  • Figure 7 is a schematic diagram showing how the tissue specific markers can target and bind to a tumor 390.
  • the bound tissue specific markers may be detected and used to distinguish the tumor from healthy neighboring tissue 395.
  • the tissue specific markers provided herein generally contain a targeting element linked to at least one indicator element.
  • the tissue specific markers may contain other elements as well such as additional targeting elements, additional indicator elements, one or more PEGylated elements, one or more linkers, and/or one or more modified residues designed to reduce degradation of the markers in the blood or at body temperature.
  • these features may enable the tissue specific markers to have one or more of the following properties: (a) the ability to selectively bind a specific tissue type with relative high affinity compared to at least one other type of tissue; (b) the ability to be detected, particularly during or prior to a surgical procedure; and/or (c) a half-life of sufficient duration to permit the tissue specific markers to bind and localize to target tissue.
  • the tissue specific markers may have several variations, depending on the specifics of their intended use.
  • the tissue specific marker contains at least a targeting element and an indicator element.
  • a targeting element e.g., aptamer or affimer component
  • an indicator element e.g., a linker molecule
  • Tissue specific markers generally include a targeting element such as an aptamer or affimer.
  • a targeting element such as an aptamer or affimer.
  • Such aptamer or affimer component typically binds to target tissue with relatively high affinity, particularly when compared to other tissues such as neighboring tissue or other undesirable tissue.
  • the affimer or aptamer selectively binds to the target tissue over at least one other tissue.
  • the aptamer or affimer of a tissue specific marker may have affinity for more than one target.
  • the aptamer or affimer may have relatively high affinity for target tissue as well as relatively high affinity for a different tissue.
  • the aptamer binds to the non-malignant target tissue with an affinity or a binding affinity (K d or dissociation constant) within a range of 1 pM to 1 mM.
  • the aptamer or affimer component of the tissue specific markers provided herein has high affinity for parathyroid tissue, particularly healthy or normal parathyroid tissue.
  • the targeting elements have high affinity for one or more abnormal (e.g., adenoma, hyperplasia or malignant tumor) parathyroid tissue.
  • an aptamer or affimer component may specifically bind to one of the following tissues: parathyroid, nerve, reproductive organ, cervix, ovary, endometrium, breast, colon, fallopian tube, gall bladder, jejunum, liver, lung, esophagus, pancreas, pituitary, placenta, prostate, skin, spinal, stomach, testes, tonsil, ureter, kidney, muscle, spleen, bladder, cerebellum, brain cortex, or other tissue.
  • the bound tissue is parathyroid tissue, nerve tissue and/or reproductive tissue (e.g., tissue derived from cervix, ovary, endometrium or other female reproductive organ).
  • the aptamer or affimer component may specifically bind to tissue that originated from an endodermal, ectodermal, or mesodermal germ layer.
  • the targeting element binds to organ tissue, particularly a solid organ or gland.
  • a targeting element provided herein generally can selectively bind to a specific tissue over undesirable tissue.
  • Such undesirable tissue may be tissue neighboring or adjacent to target tissue.
  • the targeting element selectively binds to parathyroid tissue (healthy, abnormal, or both) with higher affinity than to thyroid tissue.
  • the tissue specific markers bind with relatively high affinity to the target tissue with minimal off-target binding.
  • the aptamer selectively binds to a parathyroid gland or a parathyroid adenoma with an affinity at least 2-fold, at least 5-fold, at least 10-fold or at least 20- fold higher than an affinity of the aptamer to a thyroid gland.
  • aptamer generally refers to oligonucleotides or peptides that specifically or selectively bind to a target (e.g., target tissue, target molecule, target cell).
  • oligonucleotide aptamers may contain DNA, RNA, and/or modified nucleic acids in any combination.
  • oligonucleotide aptamers may be entirely or partially made up of DNA or RNA; while in other cases they may comprise both DNA and RNA.
  • the oligonucleotide aptamers provided herein likely bind to target molecules or tissue through non-Watson/Crick interactions.
  • the aptamers and/or affimers provided herein do not occur naturally.
  • the aptamers and/or affimers may comprise a sequence that does not occur in nature or may have one or more modifications that do not occur in nature.
  • Affimers can be small peptides or proteins, generally with a molecular weight less than 12 kDa.
  • Aptamers or affimers can have the capacity to recognize specific epitopes or antigens, and with binding affinities that can be close to those of antibodies (e.g., in the low nanomolar to picomolar range); however, the terms "aptamer” or "affimer,” as used herein, do not encompass antibodies, immunoglobulins, Fab regions of antibodies, or Fc regions of antibodies.
  • Aptamers can have the same specificity advantage of antibodies, but can be smaller, can be chemically synthesized or chemically modified, and have the advantage of being free from cell culture contaminants.
  • the aptamers and affimers provided herein may be non-immunogenic or demonstrate limited ability to provoke an immune response.
  • the aptamers and affimers provided herein may, in some cases, be able to bind to extracellular targets, a characteristic that is important for designing tissue specific markers. Once designed and selected, aptamers are generally stable, easy to handle and inexpensive to manufacture. Their chemical composition also allows the integration of a broad range of indicator elements.
  • Aptamers provided herein can be any length or size. In some cases, an aptamer provided herein is in the range of 80-100 nucleotides in length. In some cases, the aptamer is up to 100 nucleotides in length.
  • Aptamers can be selected and designed depending on their desired function.
  • the SELEX process when applied to aptamers, can comprise multiple steps. Steps include synthesis of a very large oligonucleotide library consisting of unique randomly generated sequences. Sequences can be of fixed length, and can comprise 5' and 3' ends that are shared amongst portions of the library or the entire library. The 5' and 3 ' ends can be configured to serve as primer recognition sequences for amplifying sequences in the library.
  • the sequences in the library can be exposed to a target ligand (e.g., a protein, small organic molecule, tissue, etc.), and those sequences that do not bind to the target ligand can be removed (e.g., by washing, through affinity chromatography or other means).
  • Bound sequences can be eluted and amplified by PCR to prepare for subsequent rounds of selection.
  • the stringency of the binding conditions can be increased to identify and select for the aptamer sequences with a high affinity or selectivity for target ligand.
  • SELEX method that have been used for aptamer selection, including counter selection, in which aptamers are selected for their property of binding to a different target, and are then discarded.
  • the aptamer component of a tissue specific marker provided herein may contain a sequence identical or similar to any one of SEQ ID NOs: 1-200.
  • the aptamer comprises a sequence with at least 70% sequence identity to any one of SEQ ID NOs: 1-200, at least 80%) sequence identity to any one of SEQ ID NOs: 1-200, at least 85%> sequence identity to any one of SEQ ID NOs: 1-200, at least 90% sequence identity to any one of SEQ ID NOs: 1- 200, or at least 95% sequence identity to any one of SEQ ID NOs: 1-200.
  • the aptamer component of a tissue specific marker provided herein may contain a sequence identical or similar to any one of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, or SEQ ID NO:
  • the aptamer comprises a sequence with at least 70% sequence identity to any one of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:
  • SEQ ID NO: 101 SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, or SEQ ID NO: 105, at least 80% sequence identity to any one of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4,
  • SEQ ID NO:5 SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, or SEQ ID NO:
  • SEQ ID NO: 104 or SEQ ID NO: 105, at least 90% sequence identity to any one of SEQ ID NO: 1,
  • SEQ ID NO:2 SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO: 101, SEQ ID NO: 102,
  • SEQ ID NO: 103 SEQ ID NO: 104, or SEQ ID NO: 105, or at least 95% sequence identity to any one of SEQ ID NO: l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:
  • the aptamer comprises a sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ
  • the aptamer comprises a sequence with at least 70% sequence identity to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5,
  • the aptamer comprises a sequence with at least 80% sequence identity to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5,
  • the aptamer comprises a sequence with at least 90% sequence identity to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5,
  • the aptamer comprises a sequence with at least 95% sequence identity to SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5,
  • SEQ ID NO: 103 SEQ ID NO: 104 or SEQ ID NO: 105.
  • the aptamer may comprise a sequence that includes a GATACTG motif.
  • the aptamer may comprise a GATACTG motif with 1, 2, 3, 4 or more nucleotide substitutions, insertions, transpositions or deletions.
  • the aptamer may comprise a sequence that includes GANACTG motif, wherein N is dG, dC, dT, or dA.
  • an aptamer comprises an inverted T at a 3' end of the aptamer.
  • the aptamer or affimer may localize the marker to the targeted tissue, but for such targeting element to be detected it is preferably coupled to one or more indicator elements 410 that produces a signal that can be detected by the surgeon or that can otherwise be detected by a probe or detector instrument.
  • the indicator elements can be detected by the surgeon either through the skin for preoperative applications or intraoperatively, within the surgical site.
  • the indicator element may be any type of detectable label including a fluorophore, a dye, a nanodiamond, a quantum dot, gold nanoparticle, nanorod (e.g., gold nanorod), magnetic bead, iron oxide or gold particles, aggregation-induced emission dot, or a nanocrystal.
  • the indicator element can emit visible light or near infrared when exposed to or excited by energy.
  • the markers may be easily detected directly, through paramagnetism, optoacoustics or optically either within the visible light spectrum or outside of the visible region, for example in the near-infrared, with the use of a probe or a detector instrument (e.g., a complementary metal- oxide-semiconductor (CMOS) camera, a charge coupled display (CCD) camera).
  • CMOS complementary metal- oxide-semiconductor
  • CCD charge coupled display
  • a signal from an indicator element may be detected above the skin in order to identify the location of a tissue specific marker that has already been introduced into a patient. Detection of a tissue specific marker in such manner may assist the surgeon in deciding, for example, where to make an incision or if the surgical procedure needs to occur.
  • an indicator element may be detected after the surgery has begun to distinguish the targeted tissue from neighboring tissue either when removing the targeted tissue or when removing tissue adjacent to the targeted tissue.
  • the tissue specific marker as seen in Figure 8C may contain a second indicator element 425 that can be coupled as well to the aptamer or affimer or any other part of the tissue specific marker including the first indicator element 410.
  • the marker may be PEGylated as shown by polyethylene glycol moiety 420. In other examples, the marker may not be PEGylated.
  • the tissue specific marker as seen in Figure 8C may be used to identify the target tissue preoperatively and/or during a surgical procedure.
  • the first indicator element may be used during a surgical procedure to locate the target tissue, or the undesirable tissue, as described herein and/or the second indicator element may be used preoperatively.
  • the first indicator element may be any indicator element and need not be an indicator element that is detectable through the skin.
  • the second indicator element may allow the tissue specific marker, and by extension targeted tissue, to be located preoperatively, before the surgeon makes an incision. A signal emitted by the second indicator element may often be detectable through the skin.
  • the second indicator element may contain a nanodiamond, iron oxide particles, etc. in some instances.
  • preoperative identification of the tissue specific marker may, for example, enable the surgeon to make a better informed decision when deciding if surgery is necessary or when selecting an incision site.
  • the tissue specific marker contains: (a) a parathyroid-specific aptamer or affimer; (b) a first indicator element that is a fluorophore; and (c) a second indicator element that is detectable through the skin, such as a nanodiamond or a paramagnetic bead.
  • the first and the second indicator elements generally are distinguishable.
  • One or both of the indicator elements may be optoacoustic or magnetic.
  • One or both indicator elements may comprise a bead, fluorophore, nanoparticle such as a gold nanoparticle, nanorod such as a gold nanorod, quantum dot, nanocrystal or combination thereof.
  • the first and second indicator elements are the same type of indicator element such as a fluorescent protein and are distinguishable by color or emission wavelength.
  • the first and second indicator elements are different types of indicator elements (e.g., nanodiamond and an Indocyanine Green (ICG) fluorophore).
  • the indicator element may comprise a pH sensitive molecule.
  • any number of indicator elements may be coupled to the aptamer or affimer to allow detection by any number of means including visualization by the surgeon, or by use of a probe or other device that can detect the indicator element.
  • an aptamer can be synthesized with an amine group at the 5' end, to which an indicator element (e.g., fluorophore) can be conjugated.
  • an indicator element e.g., fluorophore
  • Fluorophores can be included that emit in the visible or in the near-infrared range.
  • the first indicator element is a fluorophore and the second indicator element is a different fluorophore.
  • the indicator elements may be attached to the same aptamer or affimer or to different aptamers or affimers.
  • At least 1, at least 2, at least 3, at least 4, or at least 5 indicator elements attached to different aptamers or affimers are used. In some cases, at least 1, at least 2, at least 3, at least 4, or at least 5 indicator elements attached to the same aptamer or affimer are used.
  • Aptamers or affimers provided herein can be conjugated with indicator elements including near-infrared dyes or cyanine dyes such as Indocyanine Green (ICG).
  • indicator elements including near-infrared dyes or cyanine dyes such as Indocyanine Green (ICG).
  • ICG Indocyanine Green
  • a non-limiting list of near-infrared indicator elements that may be used in the present disclosure includes: ICG, IRDye800CW, non-sulfonated cyanine dyes, conjugated copolymers, quantum dots, aggregation- induced emission dots, metal nanoclusters, single-walled carbon nanotubes, IR-PEG
  • nanoparticles and/or infrared fluorescent proteins.
  • the indicator element can be directly conjugated to various portions of the aptamer, or may be attached using linkers or other means of covalently attaching the dye.
  • an aptamer can be synthesized with an amine group at the 5' end, to which an indicator element (e.g., fluorophore or dye) can be conjugated.
  • the tissue specific marker may need to remain intact for a long enough period of time so that it can localize and bind to target tissue and present a signal before being degraded or cleared (excreted) from the body.
  • the tissue specific marker may be synthesized using modified nucleotides or nucleosides, which can reduce or prevent degradation.
  • the tissue specific marker may optionally be chemically modified.
  • the tissue specific marker may be PEGylated, or modified to contain at least one bulky polyethylene glycol moiety 420, to reduce clearance of the tissue specific marker via the bloodstream.
  • the aptamer or affimer can contain modifications designed to increase stability and prevent degradation.
  • the tissue specific marker can be modified or chemically altered to be more resistant to DNases in the blood.
  • a tissue specific marker provided herein can have a clearance time or half-life of about or at least about 2, 3, 4, 5, 10 or 20 minutes.
  • aptamer modifications can include, but are not limited to, PEGylation, chemical modification of the nucleic acid backbone using nucleotide analogs, the addition of an inverted T at the 3' end of the aptamer, incorporation of locked nucleic acid (LNA molecules) that contain methylene bridges, and conjugation to other functional groups such as PEG and cholesterol.
  • Aptamer stability can be tested in vitro. Experiments can demonstrate that introducing modifications to the aptamers (e.g., addition of inverted T at the 3' end of the aptamer, or PEGylation of the aptamer) can reduce aptamer degradation and allow the aptamers to demonstrate better performance at a range of temperatures and conditions.
  • aptamer stability can be tested by incubating an aptamer with blood and removing aliquots over time.
  • the DNA can be isolated, and a qPCR reaction can be run to quantify the amount of aptamer that remains intact as a function of incubation time.
  • tissue specific markers can be used intraoperatively and/or preoperatively.
  • An example of an intraoperative method of using the tissue specific marker is shown in Figure 9.
  • First the marker is administered to the patient 510; this administration may be transdermal, oral, intravenous, through a spray, or by flooding. Administration may include a washing step, or multiple washing steps.
  • the aptamer or affimer component of the tissue specific marker binds with high specificity to the targeted tissue 515. In the case where the design of the maker has only one indicator, an incision is made to uncover the surgical site.
  • the surgical site is then exposed and can be excited by energy, for example near-infrared, and the indicator element will produce a detectable spectral signal 520. In some cases, the surgical site is not excited. Since the tissue specific marker containing the indicator element is uniquely localized to the target tissue and not neighboring tissue, only the target tissue will produce the spectral signal, allowing the surgeon to clearly distinguish one tissue from the other. In the intraoperative use of the tissue specific marker in thyroidectomy or parathyroidectomy procedures ( Figure 10) the surgeon may make an incision 630 in the frontal middle of the neck 615, chin 610 of patient is illustrated in Figures 10A-F for perspective.
  • the tissue specific marker may be used to mark the parathyroid tissue 625 as seen in Figure 10A, and upon excitation shown in Figure 10B the tissue specific marker specifically located in the parathyroid tissue may produce a signal 635 that the surgeon can detect and use to guide the procedure enabling removal of the thyroid tissue 620 while leaving the signal producing parathyroid tissue 635 intact or can enable the removal of the affected parathyroid gland or glands with minimal disruption to neighboring thyroid tissue 620.
  • the tissue specific marker can also be used intraoperatively, as shown in Figure IOC, to specifically label parathyroid tissue including adenoma tissue 640.
  • the aptamer or affimer component localizes to adenoma tissue 640 which upon excitation, shown in Figure 10D, produces a signal 645 that the surgeon can use to easily identify and remove the adenoma tissue from neighboring tissue.
  • the aptamer can either be specific for parathyroid adenoma, and not normal parathyroid, or it can be designed to recognize both.
  • the doctor or surgeon may elect to administer two or more markers simultaneously, for example one targeted specifically to abnormal tissue, for example an adenoma 640, and another one for example healthy thyroid tissue 620, and the doctor or surgeon may use the presence or absence of a signal from the targeted tissue to extract an affected parathyroid while avoiding the healthy parathyroid glands as well as the thyroid tissue.
  • tissue specific markers the surgeon can build a surgical roadmap, where multiple critical tissues are highlighted. For example, differentiating sentinel lymph nodes from normal nodes during removal of cancerous breast tissue.
  • the tissue specific markers may also be used preoperatively as a diagnostic to guide a doctor or surgeon in deciding whether a surgical procedure is necessary, or it may also be optionally used to guide the selection of an incision site once a diagnosis has already been made.
  • the tissue specific marker may be localized to the target tissue, for example the adenoma 640 shown in Figure 10E, and using a detector the doctor or surgeon may detect a signal 645 from the tissue specific marker as illustrated in Figure 10F.
  • the doctor or surgeon may detect the signal from the tissue specific marker, and may further use the signal to guide selection of an incision site before making an incision.
  • This tissue specific marker can be used pre- and intraoperatively, until an optional second marker's signal (e.g., fluorescence) is visible.
  • Figure 11 illustrates options that may be used for combining preoperative and
  • the tissue specific marker can be administered to the patient 710, and the aptamer or affimer may then bind to the targeted tissue 715.
  • the doctor or surgeon may use a detector to identify the location of the target tissue through the one or more indicator elements of the tissue specific marker 720.
  • the doctor or surgeon may administer the tissue specific marker to a targeted tissue, and the indicator element of the tissue specific marker may be detected by a probe or detector 650 through the patient's skin prior to surgery as shown in Figure 10F, or it may be visually observed by the doctor or surgeon.
  • FIGs 12A-12B illustrate the use of a probe to detect the tissue specific marker for diagnostic or preoperative purposes.
  • the doctor 740 or surgeon may use a probe 735 to detect the presence or absence of a signal from the patient 730 to assist in making a diagnosis.
  • the doctor 740 or surgeon may use a probe 735 to detect the tissue specific marker for making a better informed decision about the location of the target tissue allowing precise selection of an incision site using any of the techniques described herein. Further, the surgeon may expose or excite the surgical site with energy and use the tissue specific marker to distinguish the targeted tissue 725 from neighboring tissue.
  • This disclosure includes systems for differentiating target tissue from adjacent tissue.
  • the system comprises a tissue specific marker described herein and a probe for exciting one or more indicator elements with energy.
  • the system comprises a probe for detecting the signal from the one or more indicator elements.
  • the excitation probe may be attached to or separate from the detector probe.
  • the system comprises: a tissue-specific marker described herein; a second tissue specific marker, comprising a second aptamer or a second affimer configured to bind to a second pre-selected target tissue.
  • the second tissue specific marker may comprise one or more second indicator elements coupled with the second aptamer or the second affimer, wherein the second indicator element produces a signal when exposed to or excited by energy thereby allowing identification of the second target tissue.
  • Such system may comprise a first probe for exciting the first and/or second tissue specific marker with energy.
  • Such system may comprise a probe for detecting the signal from the one or more indicator elements.
  • such system may comprise a second probe for exciting the second tissue specific marker with energy.
  • Such system may also contain a second probe for detecting the signal from the one or more second indicator elements.
  • a system described herein further comprises an illumination source.
  • a system described herein further comprises a camera.
  • the system may comprise a complementary metal-oxide-semiconductor (CMOS) camera or a charge coupled display (CCD) camera.
  • CMOS complementary metal-oxide-semiconductor
  • CCD charge coupled display
  • Example 1 Selection of Aptamers that Selectively Bind Parathyroid Tissue
  • Figure 13 illustrates the design of the SELEX process that resulted in the isolation of aptamers that bound parathyroid with high affinity and did not bind normal thyroid tissue.
  • single stranded DNA aptamers that bind specifically or with high affinity to parathyroid tissue can be selected using SELEX procedures known in the art.
  • the selection library included oligonucleotide sequences 84 nucleotides in length, of which 40 nucleotides were randomized, the first 23 nucleotides (5'-
  • TAGGGAAGAGAAGGACATATGAT-3 ' were conserved and served as the forward primer recognition sequence, and the last 21 nucleotides (5 ' -TTGACT AGT AC ATGACC ACTT-3 ' ) were conserved and served as the reverse primer recognition sequence.
  • the library of aptamers was allowed to bind to normal human parathyroid tissue on a slide at room temperature. After 15 minutes, the slide was washed and all aptamers that were not tightly bound were eluted and discarded; the resulting library was amplified by PCR. The selection strategy also included alternating negative selection with normal human thyroid tissue.
  • the library of sequences that was selected by specifically binding to parathyroid and amplified was allowed to bind to normal thyroid tissue slides. After incubation, the bound aptamers were discarded, and the ones that did not bind thyroid were selected and amplified with PCR. In this fashion, normal human parathyroid and thyroid tissue slides were used alternatively to select aptamers that bind parathyroid with much higher affinity than to thyroid. Negative selection allowed the identification and removal of those aptamers that even though they may exhibit a high affinity for parathyroid, also bind tightly to thyroid, and therefore discarded.
  • Figure 14 illustrates a plot of the copy number of 10 different sequences in selection rounds 9-14 selected for twelve selection rounds for alternating parathyroid and thyroid tissues, and two subsequent selection negative selection rounds for thyroid tissue, plotted against the selection round. It can be seen in Figure 14 that both SEQ ID NO:3 and SEQ ID NO:4 increase under positive selection conditions (selection round 12) and decrease in copy number
  • Figure 15 illustrates a sequence alignment of SEQ ID NO: 103 and SEQ ID NO: 104.
  • SEQ ID NO: 103 and SEQ ID NO: 104 are the variable regions of SEQ ID NO: 3 and SEQ ID NO:4, respectively, without the common primer recognition sequences.
  • the two sequences were aligned using the EMBOSS Needle pairwise nucleotide sequence alignment.
  • the alignment, shown in Figure 15, shows a common 5'- GATACTG-3' motif in the two sequences, which is underlined in the sequences for SEQ ID NO:3 and SEQ ID NO:4 in Table 1 and in the sequences for SEQ ID NO: 103 and SEQ ID NO: 104 in Table 2.
  • SEQ ID NO:3 and SEQ ID NO:4 displayed high binding selectivity for human parathyroid tissue over human thyroid tissue. Based on analysis of the effect of positive selection for negative targets, it was determined that aptamer sequences SEQ ID NO:3 and SEQ ID NO:4 exhibited particularly promising specificity for binding to parathyroid tissue. SEQ ID NO:3 and SEQ ID NO:4 were tested on the same healthy human parathyroid slides to confirm that in fact they had high affinity for the parathyroid tissue that was used for positive selection. The results indicated that aptamers SEQ ID NO: 3 and SEQ ID NO:4 both bind well to healthy human parathyroid.
  • FIG. 16 shows the generic protocol for testing the specific binding of aptamers to tissue slides.
  • 6-FAM Fluorescein-labeled aptamer at a concentration of luM was allowed to bind to the tissue on the slide for half an hour and is then washed twice with PBS.
  • This protocol can be tested by either using a single tissue slide as a target, or by using a tissue microarray, in which a number of diverse tissues are represented, for example in triplicate. This allows a competitive assay, were the labeled aptamer has the freedom to bind to any tissue. After stringent washing, only the tissues to which the aptamer is bound with high affinity will show a positive
  • Figure 17A-G confirms the binding of SEQ ID NO:3 to normal human parathyroid tissue slides, the same exact tissue that was used for its selection.
  • Figure 18A-G confirms the binding of SEQ ID NO:4 to normal human parathyroid tissue slides, identical to the slides used for its positive selection.
  • Figure 19 shows the lack of binding to normal thyroid tissue slides, similar slides to the ones used for the negative selection of the aptamers.
  • Figure 19A shows SEQ ID NO:3 binding to thyroid;
  • Figure 19B shows SED ID NO: 4 binding to normal thyroid.
  • Figure 20A and Figure 20B show the results of the binding to parathyroid adenoma of SEQ ID NO:3 and SEQ ID NO:4, respectively.
  • FIGS. 21A and 21B show the results of the binding of SEQ ID NO:3 and SEQ ID NO:4 on two additional and unrelated parathyroid samples, respectively, proving that the aptamers were specifically targeting parathyroid and not donor-specific determinants.
  • Example 4 Analysis of Aptamer Binding to Adipose, Lymph Node, Oropharynx, and Thymus Samples [0135]
  • the selected aptamers For the selected aptamers to work in a surgical thyroidectomy environment, for example, it is required that the aptamers not only bind specifically to their cognate target, but also exhibit very little, if any, binding to neighboring tissues. In this case, it is required that the aptamers exhibit minimal or no specific binding properties to fat, lymph nodes or thymus (in children).
  • tissue samples were visualized on a microscope using FITC settings. Each tissue was controlled for background fluorescence to accurately determine specific binding versus no binding.
  • Figure 22 A and 22B display the binding of SEQ ID NO: 3 and SEQ ID NO 4 to adipose tissue, respectively.
  • Figure 23A and 23B display the binding of SEQ ID NO: 3 and SEQ ID NO 4 to lymph node tissue, respectively.
  • Figure 24A and 24B illustrate the binding of SEQ ID NO:3 and SEQ ID NO 4 to oropharynx tissue, respectively.
  • Figure 25A and 25B illustrate the binding of SEQ ID NO: 3 and SEQ ID NO 4 to child normal thymus tissue, respectively.
  • the aptamers bound to all tested parathyroid samples, but consistently did not bind to thyroid, fat, thymus or oropharynx tissues.
  • Example 5 Biodistribution: Analysis of Aptamers Binding to a Variety of Normal Human Tissue Samples
  • Figure 26A maps the distribution and triplicate location of a large variety of normal human tissues on the tissue microarray slide. Data obtained from these binding assays can give an indication of the distribution of the aptamer in the patient's body once this marker is administered.
  • tissue microarrays can be used to test in vitro bio-distribution of aptamers, indicator elements, and aptamers with bound indicator elements. The results from these studies can include measurements of the lack of autofluorescence.
  • human tissue microarrays as described previously can be used as a quick and efficient way to ensure that the tissue specific marker or aptamer binds selectively to the desired tissue of interest without substantial binding to any neighboring non-target tissues. It can additionally be used to assess the relative affinity of the labeled aptamer for each of the tissues represented.
  • the exemplary microarray described herein contained 34 different normal human tissues (each in triplicate) including parathyroid, thyroid, adrenal, bladder, brain cerebellum, brain cortex, breast, cervix, colon, endometrium, fallopian tube, gall bladder, heart, jejunum, kidney, liver, lung, lymph, muscle, nerve, esophagus, ovary, pancreas, parotid, pituitary, placenta, prostate, skin, spinal, spleen, stomach, testes, tonsil, and ureter tissues.
  • Each of the three different fluorescently-labeled aptamers was tested on a microarray slide.
  • Figure 27 and Figure 28 show the binding of aptamers SEQ ID NO: 3 SEQ ID NO: 4 to the tissues represented on the microarray, respectively.
  • the aptamers where labeled with 6-FAM Fluorescein at their 5'end and diluted at a concentration of luM in PBS and allowed to bind to the microarray for 30 minutes, after which the slide was washed multiple times and images with a fluorescence-sensitive microscope.
  • the microarray studies confirmed that the aptamers selected bound to parathyroid tissue represented in the microarray with high affinity, but did not bind to the thyroid samples (see Table 3).
  • Aptamers did not bind to the majority of tissues including: muscle, skin, brain, colon, liver, lymph node, etc. (see Table 3). Surprisingly, the tested aptamers bound to placenta and some to other female reproductive organs such as cervix, ovary, endometrium, etc. (see Table 3).
  • the selected aptamers behaved differently when binding to tissues such as nerve, where SEQ ID NO:4 appeared to bind better to the nerve tissue represented on the microarray than SEQ ID NO:3. It is possible that differences in background signal from tissue around the nerves may contribute to differences in binding detection. It is also likely that given the difference not only in primary sequence but also in tertiary structure, the aptamers have different binding specificities to other organs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
PCT/US2017/046514 2016-08-12 2017-08-11 Tissue specific markers for preoperative and intraoperative localization and visualization of tissue Ceased WO2018031894A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA3033188A CA3033188A1 (en) 2016-08-12 2017-08-11 Tissue specific markers for preoperative and intraoperative localization and visualization of tissue
CN201780062879.4A CN109804071A (zh) 2016-08-12 2017-08-11 用于术前和术中组织定位和可视化的组织特异性标志物
AU2017308059A AU2017308059A1 (en) 2016-08-12 2017-08-11 Tissue specific markers for preoperative and intraoperative localization and visualization of tissue
EP17840344.0A EP3497244A4 (en) 2016-08-12 2017-08-11 TISSUE-SPECIFIC MARKERS FOR PRE-OPERATIVE AND INTRAOPERATIVE LOCALIZATION AND VISUALIZATION OF TISSUE
JP2019507152A JP2019531706A (ja) 2016-08-12 2017-08-11 術前および術中の組織の局在化および視覚化のための組織特異的マーカー

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662374213P 2016-08-12 2016-08-12
US62/374,213 2016-08-12
US201762528006P 2017-06-30 2017-06-30
US62/528,006 2017-06-30

Publications (1)

Publication Number Publication Date
WO2018031894A1 true WO2018031894A1 (en) 2018-02-15

Family

ID=61160616

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/046514 Ceased WO2018031894A1 (en) 2016-08-12 2017-08-11 Tissue specific markers for preoperative and intraoperative localization and visualization of tissue

Country Status (7)

Country Link
US (2) US20180043037A1 (cg-RX-API-DMAC7.html)
EP (1) EP3497244A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019531706A (cg-RX-API-DMAC7.html)
CN (1) CN109804071A (cg-RX-API-DMAC7.html)
AU (1) AU2017308059A1 (cg-RX-API-DMAC7.html)
CA (1) CA3033188A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018031894A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018148333A1 (en) * 2017-02-08 2018-08-16 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2019032795A1 (en) * 2017-08-09 2019-02-14 The Procter & Gamble Company APTAMERS FOR ORAL CARE COMPOSITIONS
US10308943B2 (en) 2016-02-08 2019-06-04 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2021255184A1 (en) * 2020-06-18 2021-12-23 Consiglio Nazionale Delle Ricerche Anticancer aptamers and uses thereof

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10575801B2 (en) 2016-08-11 2020-03-03 Prismatic Sensors Ab Photon counting detector
JP2021523454A (ja) 2018-05-17 2021-09-02 ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company 毛髪分析のためのシステム及び方法
MX2020012225A (es) 2018-05-17 2021-01-29 Procter & Gamble Sistemas y metodos para el analisis de la cobertura del cabello.
HK1257467A2 (zh) * 2018-06-22 2019-10-18 Master Dynamic Limited 癌症细胞检测和成像系统,过程和制品
WO2020005326A1 (en) 2018-06-29 2020-01-02 The Procter & Gamble Company Aptamers for personal care applications
EP3956451A1 (en) 2019-04-16 2022-02-23 The Procter & Gamble Company Aptamers for odor control applications
CN110441242A (zh) * 2019-08-14 2019-11-12 郑州大学 基于金刚石微悬臂梁的气体检测系统和方法
WO2021072289A1 (en) 2019-10-10 2021-04-15 Alume Biosciences, Inc. Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery
KR20230137930A (ko) * 2021-01-14 2023-10-05 알룸 바이오사이언시스 인코포레이티드 수술 절차에서 요관을 가시화하기 위한 방법 및 조성물
US12488512B2 (en) 2021-04-14 2025-12-02 Cilag Gmbh International Utilizing contextual parameters of one or more surgical devices to predict a frequency interval for displaying surgical information
US12039732B2 (en) 2021-04-14 2024-07-16 The Procter & Gamble Company Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130101508A9 (en) * 2009-04-15 2013-04-25 Lantheus Medical Imaging, Inc. Stabilization of radiopharmaceutical compositions using ascorbic acid
US20160069889A1 (en) * 2012-12-19 2016-03-10 Caris Science, Inc. Compositions and methods for aptamer screening
US20160152982A1 (en) * 2013-07-09 2016-06-02 University Of Central Lancashire Aptamers against glioma cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4235157A3 (en) * 2008-07-30 2023-11-22 Vanderbilt University Process and system for intra-operative use of fluorescence and applications of same
EP2429565A4 (en) * 2009-04-15 2012-11-14 Univ California NEURONIC OR NERVE PEPTIDES AND APTAMERS
US20120055055A1 (en) * 2010-09-02 2012-03-08 Illumin8 Outdoor Media, LLC Systems and Method for Outdoor Media Signage
CN103290019B (zh) * 2013-06-14 2014-03-12 严鹏科 一种动脉粥样硬化的靶向适配子及其制备方法和应用
US20150305623A1 (en) * 2014-04-23 2015-10-29 Invuity, Inc. Methods for localizing and treating a parathyroid adenoma
CN105675605A (zh) * 2016-03-29 2016-06-15 中国药科大学 一种利用适配体功能化的金纳米颗粒检测胆汁酸的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130101508A9 (en) * 2009-04-15 2013-04-25 Lantheus Medical Imaging, Inc. Stabilization of radiopharmaceutical compositions using ascorbic acid
US20160069889A1 (en) * 2012-12-19 2016-03-10 Caris Science, Inc. Compositions and methods for aptamer screening
US20160152982A1 (en) * 2013-07-09 2016-06-02 University Of Central Lancashire Aptamers against glioma cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3497244A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10308943B2 (en) 2016-02-08 2019-06-04 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2018148333A1 (en) * 2017-02-08 2018-08-16 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
WO2019032795A1 (en) * 2017-08-09 2019-02-14 The Procter & Gamble Company APTAMERS FOR ORAL CARE COMPOSITIONS
WO2021255184A1 (en) * 2020-06-18 2021-12-23 Consiglio Nazionale Delle Ricerche Anticancer aptamers and uses thereof

Also Published As

Publication number Publication date
EP3497244A1 (en) 2019-06-19
CN109804071A (zh) 2019-05-24
JP2019531706A (ja) 2019-11-07
CA3033188A1 (en) 2018-02-15
US20210106696A1 (en) 2021-04-15
US20180043037A1 (en) 2018-02-15
AU2017308059A1 (en) 2019-02-21
EP3497244A4 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
US20210106696A1 (en) Tissue specific markers for preoperative and intraoperative localization and visualization of tissue
Marano et al. Application of fluorescence in robotic general surgery: review of the literature and state of the art
USRE45916E1 (en) Intraoperative imaging of renal cortical tumors and cysts
ES2811065T3 (es) Variantes de clorotoxina, conjugados y métodos para su utilización
US20060173362A1 (en) Methods of medical imaging using quantum dots
US10238757B2 (en) Methods and compositions for detection of cancer
EP2076292A2 (en) Contrast agents for detecting prostate cancer
US20080194970A1 (en) Methods for Intraoperative Organotypic Nerve Mapping
CN108495655A (zh) 用于组织区分例如用于术中可视化的成像系统和方法
Mooney et al. Laser scanning confocal endomicroscopy in the neurosurgical operating room: a review and discussion of future applications
EP3193945A1 (en) Upar targeting peptide for use in peroperative optical imaging of invasive cancer
Ma et al. High-precision detection and navigation surgery of colorectal cancer micrometastases
De la Garza-Ramos et al. Fluorescent techniques in spine surgery
Tao et al. Discovery of fatty acid translocase CD36-targeting near-infrared fluorescent probe enables visualization and imaging-guided surgery for glioma
Liang et al. Clinical fluorescent probes: mechanisms, advantages and inspirations
CN114835723A (zh) Psma荧光分子探针、制备方法及试剂盒
Picasso et al. The role of chromoendoscopy in the surveillance of the duodenum of patients with familial adenomatous polyposis
JP2012524079A5 (cg-RX-API-DMAC7.html)
Zeng et al. Targeting and imaging colorectal cancer by activatable cell-penetrating peptides
KR20230009488A (ko) 가요성 프로브와 조합된 표적화 형광 마커의 사용
US20240148467A1 (en) Method of marking lesions
CN113288052A (zh) 一种通过fitc-uea1标记探查消化道肿瘤的方法
CN118078219B (zh) 近红外荧光捕获系统、装置及应用
CN113425859B (zh) 一种GnRH多肽修饰的探针、包含它的制剂、药物组合物及其制备方法与应用
Oldfield Pituitary adenoma identification

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17840344

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3033188

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2019507152

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017308059

Country of ref document: AU

Date of ref document: 20170811

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017840344

Country of ref document: EP

Effective date: 20190312